跳转至内容
Merck
CN
  • Prior extended daily access to cocaine elevates the reward threshold in a conditioned place preference test.

Prior extended daily access to cocaine elevates the reward threshold in a conditioned place preference test.

Addiction biology (2013-05-03)
Zu-In Su, Jennifer Wenzel, Aaron Ettenberg, Osnat Ben-Shahar
摘要

We have previously shown that extended-access subjects exhibit heightened motivation for cocaine in the runway model, as reflected by reduced number of retreats. This heightened motivation could reflect either an increase in cocaine-induced reward or a decrease in cocaine-induced aversion. The current experiment was therefore devised to assess the cocaine-induced reward and aversion in extended-access rats using a place conditioning test. Rats trained to lever press for intravenous (IV) cocaine (0.25 mg/infusion) were provided 6-hour daily access to the drug over 10 days. Lever pressing in control subjects produced IV infusions of saline. Following drug self-administration, subjects underwent place conditioning for the immediate or delayed effects of cocaine (1.0 or 2.5 mg/kg, IV). In control subjects, the immediate effects of the low dose of cocaine produced conditioned places preferences (CPPs), while the delayed effects produced conditioned place aversions (CPAs). In contrast, the animals receiving low cocaine dose for 6 hours, exhibited place aversions but not preferences; an effect that was reversed when the dose of cocaine was increased. Additionally, in the 6-hour group, delayed conditioning was associated with a reduction in zif268 immunoreactivity in the medial prefrontal cortex and nucleus accumbens shell while immediate conditioning was associated with an increase in zif268-positive cells in the central nucleus of the amygdala. Collectively, these data suggest that extended daily access to cocaine produces a shift in the subject's perceived reward threshold that is paralleled by alterations in the activity of both the reward and stress pathways.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
二甲基亚砜, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
二甲基亚砜, ACS reagent, ≥99.9%
Sigma-Aldrich
二甲基亚砜, Molecular Biology
Sigma-Aldrich
二甲基亚砜, suitable for HPLC, ≥99.7%
Sigma-Aldrich
二甲基亚砜, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
二甲基亚砜, ReagentPlus®, ≥99.5%
Sigma-Aldrich
二甲基亚砜, anhydrous, ≥99.9%
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
二甲基亚砜, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
二甲基亚砜, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
二甲基亚砜, BioUltra, Molecular Biology, ≥99.5% (GC)
Sigma-Aldrich
3,3-二氨基联苯胺 四盐酸盐 水合物, ≥96%
Millipore
过氧化氢 溶液, 3%, suitable for microbiology
Sigma-Aldrich
过氧化氢 溶液, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
二甲基亚砜, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
二甲基亚砜, PCR Reagent
Sigma-Aldrich
过氧化氢 溶液, 34.5-36.5%
Sigma-Aldrich
二甲基亚砜, puriss. p.a., dried, ≤0.02% water
Supelco
二甲基亚砜, analytical standard
Supelco
二甲基亚砜, for inorganic trace analysis, ≥99.99995% (metals basis)
USP
二甲基亚砜, United States Pharmacopeia (USP) Reference Standard
二甲基亚砜, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
二甲基亚砜, Vetec, reagent grade, 99%